Literature DB >> 8880166

Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

A R Willan1, B J O'Brien.   

Abstract

Application of cost-effectiveness analysis (CEA) is growing rapidly in health care. Two general approaches to analysis are differentiated by the type of data available: (i) deterministic models based upon secondary analysis of retrospective data from one or more trials and other sources; and (ii) stochastic analyses in which the design of a randomized controlled trial is adapted to collect prospectively patient-specific data on costs and effectiveness. An important methodological difference between these two approaches is in how uncertainty is handled. Deterministic CEA models typically rely upon sensitivity analysis to determine the robustness of findings to alternative assumptions, whereas stochastic (CEA) analysis, as part of prospective studies, permits the use of conventional statistical methods on the cost and effectiveness data for both inference (hypothesis testing) and estimation. This paper presents a procedure for the statistical analysis of cost-effectiveness data, with specific application to those studies for which effectiveness is measured as a binary outcome. Specifically, Fieller's Theorem was used to calculate confidence intervals for ratios of the two random variables of between-treatment differences in observed costs and effectiveness, i.e. the incremental cost-effectiveness ratio.

Entities:  

Mesh:

Year:  1996        PMID: 8880166     DOI: 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  28 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 3.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Counselling of hearing aid users is highly cost-effective.

Authors:  Arja Vuorialho; Petri Karinen; Martti Sorri
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-06-24       Impact factor: 2.503

5.  Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods.

Authors:  Jeffrey A Katula; Mara Z Vitolins; Erica L Rosenberger; Caroline Blackwell; Mark A Espeland; Michael S Lawlor; W Jack Rejeski; David C Goff
Journal:  Contemp Clin Trials       Date:  2009-09-13       Impact factor: 2.226

6.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

7.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

8.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Authors:  A Gray; M Raikou; A McGuire; P Fenn; R Stevens; C Cull; I Stratton; A Adler; R Holman; R Turner
Journal:  BMJ       Date:  2000-05-20

9.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

Review 10.  A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics.

Authors:  Richard T Meenan; Gloria D Coronado; Amanda Petrik; Beverly B Green
Journal:  Prev Med       Date:  2019-01-24       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.